Non-mitotic acidic fibroblast growth factor (NM-aFGF) inhibits myocardial oxidative stress injury and ameliorates myocardial structural and functional damage in diabetic cardiomyopathy (DCM) through activation of the AKT/GSK/Nrf-2 signaling pathway. This evidence concerns the gene AKT1 and familial dilated cardiomyopathy.